Pfizer Inc. has agreed to buy Baxter International Inc.’s vaccines business and part of a production factory for $635 million. Pzifer now has access to a meningitis vaccine, NeisVac-C, and FSME-IMMUN, a drug used to treat encephalitis. Both vaccines are on the market but not in United States. According to Pfizer, its global vaccines business had sales of $1.1 billion in the second quarter. The deal is expected to close before the end of the year.